The complaint alleges that Immutep misled the market by concealing negative outcomes from the TACTI-004 study of eftilagimod alfa. While the company filed a Form-K on January 30, 2026, describing "strong operational progress," the lawsuit contends that leadership was already aware the trial would fail to meet its primary efficacy endpoints. Shareholders who suffered financial losses due to these disclosures are encouraged to contact attorney Brian Schall by July 6, 2026.

Legal proceedings are currently in the pre-certification stage, meaning investors are not yet represented by counsel. Participation remains optional, and those who do not take action will continue to be classified as absent class members. The Schall Law Firm, based in Los Angeles, is managing inquiries regarding potential recovery for those impacted by the alleged drop in stock value following the disclosure of the trial results.